Current partner codePEPTIDESDE
NCT00948818·Phase 3·INTERVENTIONAL

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Status

Completed

Phase

Phase 3

Enrollment

803

Locations

118

Results

Posted

Publications

2

Study summary

What the protocol is testing.

The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with irritable bowel syndrome with constipation (IBS-C). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder.

Interventions

Treatment arms and agents.

DRUG

Linaclotide 290 micrograms

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

DRUG

Matching placebo

Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

Timeline

From registration to results.

  1. First posted

    Jul 29, 2009

  2. Study start

    Jul 2009

  3. Primary completion

    Jul 2010

  4. Study completion

    Aug 2010

  5. Results posted

    Jan 30, 2013

  6. Registry updated

    Jan 30, 2013

Outcomes

What the study measures.

Primary outcomes

Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks

Time frame · Change from Baseline to Week 12

A patient is considered to be an APC responder if, for at least 9 out of the 12 weeks of the treatment period, the patient had at least 3 CSBMs, experienced an increase of at least 1 CSBM from baseline, and experienced a decrease of at least 30 percent in their Abdominal Pain (AP) score from baseline during a particular week. The AP score assesses the worst of a patient's AP in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no AP and 10 represents very severe AP. A CSBM is defined as a spontaneous bowel movement, associated with a sense of complete evacuation.

Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder, 9 Out of 12 Weeks

Time frame · Change from Baseline to Week 12

A patient is considered to be a CSBM 3+1 responder if, for at least 9 out of the 12 weeks of the treatment period, the patient had at least 3 CSBMs and experienced an increase of at least 1 CSBM from baseline during a particular week. A CSBM was defined as a Spontaneous Bowel Movement (SBM) that was associated with a sense of complete evacuation. An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.

Abdominal Pain Responder, 9 Out of 12 Weeks

Time frame · Change from Baseline to Week 12

A patient is considered to be an abdominal pain responder if, for at least 9 out of the 12 weeks of the treatment period, they experienced a decrease of at least 30 percent in the mean abdominal pain score from baseline during a particular week. The Abdominal Pain score assesses the worst of a patient's abdominal pain in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no abdominal pain and 10 represents very severe abdominal pain.

Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks.

Time frame · Change from Baseline to Week 12

A patient is considered an APC responder if, for at least 6 of the 12 weeks of the treatment, the patient experienced an increase of at least 1 Complete Spontaneous Bowel Movement (CSBM) from baseline and experienced a decrease of at least 30 percent in their Abdominal Pain (AP)score during a particular week. The AP score assesses the worst of a patient's AP in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no AP and 10 represents very severe AP. A CSBM was defined as a Spontaneous Bowel Movement (SBM) that was associated with a sense of complete evacuation.

Secondary outcomes

12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency Rate

Time frame · Change from Baseline to Week 12

The number of CSBMs per week.

12-Week Spontaneous Bowl Movement (SBM) Frequency Rate

Time frame · Change from Baseline to Week 12

The number of Spontaneous Bowl Movements experienced per week.

12-Week Stool Consistency

Time frame · Change from Baseline to Week 12

The consistency of each BM was assessed by patients using the 7-point Bristol Stool Form Scale (BSFS) from 1 to 7. 1. = separate hard lumps like nuts \[difficult to pass\] 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges \[passed easily\] 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces \[entirely liquid\]).

12-Week Severity of Straining

Time frame · Change from Baseline to Week 12

Straining is measured on a 5-point scale where a value of 1 is "not at all" and a value of 5 is "an extreme amount.

12-Week Change in Abdominal Pain Score

Time frame · Change from Baseline to Week 12

Abdominal Pain at its worst (in the last 24 hours) is based on an 11-point scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain.

12-Week Change in Abdominal Discomfort

Time frame · Change from Baseline to Week 12

Abdominal Discomfort is measured on an 11-point scale where a value of 0 is "none" and a value of 10 is "very severe."

12-Week Change in Bloating

Time frame · Change from Baseline to Week 12

Bloating was assessed on an 11-point scale where a value of 0 is "none" and a value of 10 is "very severe".

Complete Spontaneous Bowl Movement (CSBM) Responder for 6 Weeks Out of 12 Weeks of Treatment

Time frame · Change from Baseline to Week 12

A patient is considered to be a CSBM responder if, for at least 6 out of the 12 weeks of the treatment period, an increase of at least 1 CSBM per week from baseline was experienced.

Abdominal Pain Responder for 6 Out of 12 Weeks

Time frame · Change from Baseline to Week 12

A patient is considered to be an abdominal pain responder if, for at least 6 out of the 12 weeks of the treatment period, they experienced a decrease of 30 percent or more in the abdominal pain score from baseline. The Abdominal Pain score assesses the worst of a patient's abdominal pain in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no abdominal pain and 10 represents very severe abdominal pain.

12-Week Percent of Abdominal Pain-free (APF) Days

Time frame · Change from Baseline to Week 12

Abdominal pain free (APF) days are those days where the patient reported a score of '0' for abdominal pain at its worst Abdominal Pain at its worst (in the last 24 hours) is based on an 11-point scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Patient meets protocol criteria for IBS: reports abdominal discomfort or pain that has two or more of the following three features: 1. Relieved with defecation 2. Onset associated with a change in frequency of stool 3. Onset associated with a change in form (appearance) of stool * Patient reports \< 3 bowel movements (BMs) per week (in the absence of any laxative, suppository, or enema use during the preceding 24 hours) and reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation during \> 25% of BMs * Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests (some patients may require a colonoscopy per American Gastroenterological Association (AGA) guidelines) * Patient is compliant with Interactive Voice Response System (IVRS) for daily diary reporting of BM habits and IBS symptoms Exclusion Criteria: * Patient has history of loose or watery stools for \>25% of BMs * Patient has a structural abnormality of the gastrointestinal (GI) tract or a history of a disease or condition that can affect GI motility * Patient has any protocol-excluded or clinically significant medical or surgical history or concomitant medication use that could confound the study assessments

Study locations

118 registered sites.

Canada · United States. Showing up to 24 locations stored in the fast local snapshot.

Forest Investigative Site 037

Birmingham, Alabama, United States

Forest Investigative Site 036

Birmingham, Alabama, United States

Forest Investigative Site 135

Hueytown, Alabama, United States

Forest Investigative Site 014

Huntsville, Alabama, United States

Forest Investigative Site 080

Chandler, Arizona, United States

Forest Investigative Site 053

Mesa, Arizona, United States

Forest Investigative Site 078

Peoria, Arizona, United States

Forest Investigative Site 101

Phoenix, Arizona, United States

Forest Investigative Site 128

Phoenix, Arizona, United States

Forest Investigative Site 051

Scottsdale, Arizona, United States

Forest Investigative Site 136

Tucson, Arizona, United States

Forest Investigative Site 087

Tucson, Arizona, United States

Forest Investigative Site 094

Burbank, California, United States

Forest Investigative Site 026

Encinitas, California, United States

Forest Investigative Site 096

Foothill Ranch, California, United States

Forest Investigative Site 057

Los Angeles, California, United States

Forest Investigative Site 097

Mission Hills, California, United States

Forest Investigative Site 005

Orange, California, United States

Forest Investigative Site 024

Westlake Village, California, United States

Forest Investigative Site 021

Boulder, Colorado, United States

Forest Investigative Site 019

Colorado Springs, Colorado, United States

Forest Investigative Site 034

Denver, Colorado, United States

Forest Investigative Site 074

Longmont, Colorado, United States

Forest Investigative Site 010

Wheat Ridge, Colorado, United States

Related trials

More studies on Linaclotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.